KIMBERLY DALE: Open Payments
NPI 1427583046 · ORLANDO, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$307 in 18 payments from 8 companies in 2025. Trend: 2023 $527 · 2024 $445 · 2025 $307
Food & beverage: $307
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 6 | $103 |
| Amgen Inc. | 3 | $45 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $41 |
| PFIZER INC. | 2 | $33 |
| ABBVIE INC. | 2 | $33 |
| Abbott Laboratories | 1 | $19 |
| Lilly USA, LLC | 1 | $17 |
| GlaxoSmithKline, LLC. | 1 | $17 |
Products named: XIFAXAN, Ozempic, Rybelsus, ELIQUIS, UBRELVY, EVENITY, FREESTYLE LIBRE 3, Wegovy.
Industry payments across FL — which companies pay providers there.
